Pharmaceutical removal from wastewater by introducing cytochrome P450s into microalgae

Abstract

Pharmaceuticals are of increasing environmental concern as they emerge and accumulate in surface‐ and groundwater systems around the world, endangering the overall health of aquatic ecosystems. Municipal wastewater discharge is a significant vector for pharmaceuticals and their metabolites to enter surface waters as humans incompletely absorb prescription drugs and excrete up to 50% into wastewater, which are subsequently incompletely removed during wastewater treatment. Microalgae present a promising target for improving wastewater treatment due to their ability to remove some pollutants efficiently. However, their inherent metabolic pathways limit their capacity to degrade more recalcitrant organic compounds such as pharmaceuticals. The human liver employs enzymes to break down and absorb drugs, and these enzymes are extensively researched during drug development, meaning the cytochrome P450 enzymes responsible for metabolizing each approved drug are well studied. Thus, unlocking or increasing cytochrome P450 expression in endogenous wastewater microalgae could be a cost‐effective strategy to reduce pharmaceutical loads in effluents. Here, we discuss the challenges and opportunities associated with introducing cytochrome P450 enzymes into microalgae. We anticipate that cytochrome P450‐engineered microalgae can serve as a new drug removal method and a sustainable solution that can upgrade wastewater treatment facilities to function as “mega livers”.

Abstract

Persistent pharmaceuticals in wastewater threaten both human and aquatic ecosystems due to incomplete treatment removal. Microalgae face challenges in degrading these drugs because of metabolic limitations. Introducing cytochrome P450 enzymes into microalgae could enhance their capacity to break down pharmaceuticals, turning treatment facilities into highly efficient “mega livers” for pharmaceutical removal.